Mucosal administration of antigens in experimental animals leads to the induction of peripheral T cell tolerance. We have previously reported that in H-2 b mice, intranasal (i.n.) or oral administration of a peptide containing the immunodominant T cell epitope will down-regulate the function of CD4 ⍣ T cells reactive with Der p 1, a major target antigen in both B and T cell responses to house dust mite. In the present study we have investigated the tolerogenicity of peptides containing both dominant and subdominant determinants when given i.n. to naive mice. Induction of tolerance by the nasally administered immunodominant peptide leads to a diminution in all T cell-derived cytokines and modulation of delayed-type hypersensitivity responses, but IgE production did not seem to be affected, furthermore the induction of T cell tolerance was stable, lasting beyond 6 months. We have also examined the specificity of intramolecular epitope suppression which is a feature of mucosal tolerance induced by nasally administered peptides and demonstrate that regulatory CD4 ⍣ T cells may exert their suppressive effect by linked recognition of epitopes on the same or neighbouring antigen-presenting cells.
Introduction
Soluble protein antigens encountered through the respiratory (8-12). Peptides derived from self antigens delivered in tolerogenic form through mucosal surfaces can prevent the or gastrointestinal tracts do not elicit strong systemic immune responses but induce a state of antigen-specific unresponsinduction of, or reduce the severity of, clinical symptoms associated with various autoimmune diseases (12-14). iveness which is commonly referred to as mucosal tolerance. It is characterized by a diminution of T cell effector responses Furthermore, we have previously reported that the intranasal (i.n.) or oral administration of a single immunodominant and consequently antibody synthesis. As regards the cellular mechanisms responsible for the development of tolerance, it peptide derived from the house dust mite (HDM) protein Der p 1, when given prior to immunization with the whole protein, appears that feeding high doses of antigen can lead to the deletion of antigen-specific T cells (1), anergy (2-4) or a shift can induce peripheral tolerance in both naive (15,16) or sensitized mice (15). The non-responsiveness is characterin the cytokine production of T cells (5). Similarly, tolerance to inhaled antigens can arise as a result of anergy or immune ized by a reduction in IL-2 production by both lymph node and splenic T cells, and their failure to provide cognate help deviation (6,7).
Early studies on mucosal tolerance were restricted to for antibody production (15). A feature of peptide-induced mucosal tolerance is that analysis of cellular responses to whole protein antigens, but it now appears that immunogenic peptides which contain treatment with a single immunogenic peptide can abrogate T cell responses to all the epitopes on an antigen T cell epitopes can also act as potent tolerogens in vivo (13-16). Such intramolecular, and presumably intermolecular Lymphokine assays (or bystander), epitope suppression seems to be effective in Cytokine measurements were made with the use of either inhibiting the onset of clinical symptoms in different autobioassays [IL-2, IL-4 and transforming growth factor (TGF)-β1] immune disease models (13, 14, 17) , where immunological or ELISA (IFN-γ and IL-5). All cytokines were measured in responses to multideterminant self antigens are typically culture supernatants taken at 24 h intervals over a 96 h involved. These studies and others (18, 19) have suggested period. IL-2 and IL-3 were usually measured at 24 h, IL-5, that peripheral T cell tolerance can occur through linked IFN-γ and TGF-β at 48 h, and IL-4 at 96 h. recognition of tolerogenic antigen which helps to block an
The CTLL-2 cell line proliferates maximally with IL-2 but antigen-specific immune response. In the present study we only poorly in the presence of IL-4 (20) . Test supernatants have investigated further the specificity and duration of the (50 µl volumes) were added to 5ϫ10 3 CTLL-2 cells (50 µl) T cell tolerance to peptides delivered i.n. to mice.
per well and cultured for 24 h at 37°C and pulsed for 6 h with IFN-γ was measured using an ELISA assay. Briefly, rat antimouse IFN-γ mAb (R4-6A2; PharMingen, San Diego, CA) was Antigens coated onto Immulon-2 plates overnight and washed with The HDM allergen Der p 1 was affinity purified from spent PBS containing 0.05% Tween 20 (Sigma). Plates were blocked mite medium (16). Synthetic peptides p81-102, p111-139 with 10% BSA dissolved in PBS. After washing, culture and p197-212 derived from the Der p 1 sequence were supernatants were added to the plates and incubated for 2 h synthesized using standard f-moc chemistry.
at room temperature. Plates were washed and the presence of bound IFN-γ detected by biotinylated anti-mouse IFN-γ Induction of tolerance by i.n. administered peptides (XMG1.2; PharMingen). Plates were developed using streptavidin-alkaline phosphatase (Sigma) with 3,3Ј-5,5Ј-tetratmethyl Mice were lightly anaesthetized under ether and peptides benzidine (Sigma) as the substrate and plates were read at dissolved in PBS were administered i.n. in a total volume of 405 nm. The concentration of IFN-γ was measured from a 20 µl using a micropipette on three consecutive days. Mice standard curve using recombinant IFN-γ (PharMingen). were immunized s.c. at the base of the tail 14 days after the IL-5 was measured in 48 h culture supernatants by ELISA last treatment with 50 µg of Der p 1 emulsified in complete using a commercially available kit (Endogen IL-5) and was Freund's adjuvant (CFA; Difco, Detroit, MI) in a volume of performed following the manufacturer's directions. Standard 0.2 ml. Ten days later the para-aortic and inguinal lymph recombinant IL-5 preparations were included in each assays. nodes were collected and cell suspensions made. To examine bystander suppression to an unrelated antigen, peptide-TGF-β1 treated or control mice were co-immunized with 50 µg Der p 1 and ovalbumin (OVA) in CFA.
The growth of the mink lung epithelial cell line MV-1Lu is arrested in the presence of TGF-β1. Test supernatants (50 µl Culture medium volumes) were added to 2ϫ10 3 MV-1Lu cells (50 µl) per well and cultured for 24 h at 37°C and pulsed for 6 h with Lymph node (LN) or spleen cells were cultured in RPMI [ 3 H]thymidine. The concentration of TGF-β1 in supernatants 1640 (Gibco, Grand Island, NY) supplemented with 2% FCS was determined from a standard curve using purified TGF-β1. (Gibco), 50 µM 2-mercaptoethanol (Sigma, St Louis, MO), 2 mM L-glutamine (Sigma) and 20 µg/ml penicillin/streptomySkin testing for delayed-type hypersensitivity (DTH) responses cin. CTLL-2 and MV1-Lu cells were maintained in RPMI 1640 and 10% FCS, and FDC-P1 cells were cultured in DMEM Mice received either PBS or p111-139 nasally on three (Gibco) plus 5% FCS.
consecutive days and 9 days later mice were immunized with 100 µg Der p 1/CFA. After 7 days mice were injected T cell assays intradermally with 10 µg Der p 1 in 10 µl PBS. Ear swelling was measured after 24 h and the increments were obtained LN cells were pressed through a stainless steel wire mesh,
by subtracting values of the test groups from those control washed and cultured at 4ϫ10 5 cells in a volume of 0.2 ml in mice who received either PBS or p111-139 alone. culture medium in a 96-well flat-bottom tissue culture plate (Nunc, Copenhagen, Denmark). Peptide antigen was added Passive cutaneous anaphylaxis (PCA) assay at various concentrations and the cells were incubated at 37°C for 24 or 48 h. Supernatants were collected and stored
Mice were treated nasally with PBS or a tolerogenic dose of peptide 111-139 and then immunized 9 days later with Der at -20°C until required for the assay. p 1/CFA. After 21 days mice were bled and the serum was tered peptide. To determine if this can be correlated with an in vivo response, we compared DTH responses in mice serially diluted in doubling dilutions in PBS. Serum was injected intradermally into the back of an adult male Spraguereceiving either PBS or p111-139 nasally. Mice were tolerized as usual and after 9 days were immunized with 100 µg Dawley rat. After 24 h the rat was anaethetized and injected with 10 µg of Der p 1 in saline containing Evans blue. Serum
Der p 1/CFA. One week later all mice were immunized intradermally in the ear with 10 µg of Der p 1. Specific skin from Der p 1 hyperimmunized mice was used as a positive control. A positive result was scored at the serum dilution swelling was measured 24 h later. To determine background swelling responses, mice were pretreated with PBS or p111-which gave a wheal of 10 mm or larger.
139 alone and received no Der p 1/CFA injection. The data Statistical analysis presented in Fig. 2 Alternatively, mice were treated with 100 µg p 1-derived peptides containing either the immunodominant of p111-139 i.n. on 3 consecutive days and immunized (p111-139) or a minor (81-102) epitope to inhibit antigen-6 months after the initial treatment and responses examined specific CD4 ϩ T cell responses when administered nasally in vitro 10 days after immunization with Der p 1/CFA. T cells was investigated. In all the experiments performed in this from PBS-treated control mice responded well to p111-139 report, control mice received PBS i.n., but the specificity of in vitro and were capable of secreting IL-2 (Fig. 3) , whereas LN tolerance induction of this model has been previously reported cells from peptide-treated animals, i.e. from 2 week or 6 month (15). Mice were treated with either PBS or with 100 µg groups, were still unresponsive to the antigen in vitro (Fig. 3) . of p111-139 or p81-102 on three consecutive days and immunized with Der p 1/CFA 14 days after the last peptide Characterization of intramolecular epitope suppression treatment. The capacity of LN T cells to secrete various A feature of peripheral tolerance induced by mucosally cytokines following in vitro stimulation with the Der p 1 protein delivered peptide is that treating mice with a single peptide 10 days after the parenteral challenge was examined. All can inhibit T cell responses to all epitopes on the antigen cytokines were measured at various time points from 24 to (13,15), which we define here as intramolecular epitope 96 h in order to determine the optimal secretion and for suppression. We wanted to examine therefore the antigenic simplicity cytokines shown in Fig. 1 are only from the peak requirements that were necessary for this phenomenon to be response. T cells from control mice were still highly responsive observed in vivo. Mice were treated with either PBS or p111-to the Der p 1 protein in vitro and could secrete IL-2, IL-3, 139 i.n. and 2 weeks later immunized with either 50 µg of Der IL-5, IFN-γ but with little or no IL-4, while T cells from mice p 1/CFA, p111-139/CFA or p81-102/CFA. LN T cells from treated with HDM peptide displayed down-regulated cytokine control mice were responsive to each of the immunogens responses in vitro for all the cytokines measured (Fig. 1) . In when stimulated in vitro (Fig. 4A-C) . T cells from mice treated addition, we did not observe any increase in TGF-β1 secretion with p111-139 i.n. failed to secrete IL-2 when stimulated following tolerance induction to nasally administered peptides in vitro with Der p 1 or p111-139 ( Fig. 4D and E) . However, (Fig. 1) . The level of tolerance achieved with the minor epitope tolerance could not be demonstrated to the minor peptide was not as complete as that obtained with the dominant in vitro if mice pretreated with p111-139 i.n. were immunized peptide, with the minor epitope only reducing responses to with p81-102/CFA (Fig. 4F) . 50-60% of that observed in the control animals (Fig. 1) . In all
The previous results suggest that the intact protein is of the remaining experiments we have focused on the secrerequired in order to observe intramolecular epitope supprestion of IL-2 by LN T cells since this is the cytokine that is most sion. The temporal relationship of tolerance to the dominant markedly inhibited in T cells following mucosal tolerance and and minor epitopes was investigated. Mice were treated i.n. is a general feature of peripheral T cell tolerance.
with PBS or p111-139 and 14 days later immunized with Der Peptide tolerance affects DTH responses but not IgE p 1/CFA. In one group in vitro T cell responses to the protein responses and to a minor epitope were examined after the usual 10 day period. T cells from control mice responded well to both Der The above results indicate that T cell responses are markedly reduced following induction of tolerance to nasally adminisp 1 and to the minor epitope, p197-212 ( Fig. 5A and B) . However, mice that were pretreated with p111-139 showed responses to the minor epitope 197-212 ( Fig. 5C and D) , while T cell responses in both groups to the dominant epitope down-regulated responses to the protein and to p197-212 ( Fig. 5A and B) . The remaining mice were immunized with 50 were still down-regulated. µg of 197-212/incomplete Freund's adjuvant (IFA) 3 weeks Bystander suppression after the Der p 1 challenge, and after a further 10 days LN cells from both groups were tested for responses to the
The previous experiments demonstrate that the nasally administered immunodominant peptide can induce regulatory T cells dominant and minor epitopes. When analysed, T cells from control mice and peptide-tolerated mice displayed equivalent that can block T cell responses to epitopes linked on the iveness, which is referred to as mucosal tolerance. We have previously reported that i.n. administration of the immunodominant peptide (residues 111-139) derived from the Der p 1 allergen of HDM can specifically inhibit CD4 ϩ T cell responses to the whole antigen when administered to naive or sensitized H-2 b mice (15). Several mechanisms have been identified to explain the loss of T cell antigen-reactivity following the induction of mucosal tolerance. Clonal deletion of antigenreactive T cells has been observed following high-dose feeding of protein antigens to TCR transgenic mice (1), while others have suggested a role for clonal anergy of CD4 ϩ T cells (2,3). In addition there is evidence for active suppression in oral tolerance mediated by TGF-β1 CD8 ϩ T suppressor (T s ) and, more recently, immunoregulatory CD4 ϩ T cells that secrete T h 2-type cytokines (e.g. IL-4, IL-10 and TGF-β1) have tolerance (2,3,21). Studies on the immune response to nebulized antigens have revealed that allergic sensitization is naturally avoided same protein. We wanted to examine if these regulatory T cells through a shift in cytokine production (or immune deviation) may also block immune responses to unrelated antigens by specific CD4 ϩ T cells during the course of a primary in vivo. Mice were tolerated with the dominant peptide as immune response to the antigen (7). There is evidence that usual but on day 14 post-treatment mice were co-immunized regulatory CD8 ϩ T s cells become activated following inhalation with Der p 1 and OVA in CFA. Ten days later LN cells were of protein antigen in experimental animals which can block cultured in vitro and responses tested to Der p 1 or OVA antigen-specific IgE synthesis in vivo (22) (23) (24) (25) . However, it separately. As shown in Fig. 6 , T cell responses to Der p 1 were was recently shown that CD8 ϩ T cells activated by inhaled clearly abrogated (P Ͻ 0.05) but although some decrease in antigen may play a role in mediating airway hypersensitivity T cell responses was observed to the bystander antigen OVA, (26) . In addition immune deviation was shown to be responsthis was not statistically significant (P Ͼ 0.1).
ible for the protection of non-obese diabetic mice from autoimmune diabetes following nasal administration of a Discussion cocktail of GAD65 peptides (27) . The delivery of antigens through mucosal surfaces is an Induction of tolerance to high-dose nasally administered peptide is preceded by a transient response by CD4 ϩ T cells efficient way of inducing antigen-specific T cell non-respons- (6). We have not identified a role for CD8 ϩ T cells in this contrast to studies on oral tolerance to MBP where TGF-β secretion seems to be an important mechanism for regulating model (6) and interestingly do not observe any shift in cytokine production or increased secretion of TGF-β1 by regulatory responses of self-reactive CD4 ϩ T cells. In the model studied here, the production of all T-cell-derived cytokines was down-T cells following i.n. peptide tolerance. This clearly is in The data show the production of IL-2 in culture supernatants from individual mice stimulated with 20 µg/ml Der p 1 or 400 µg/ml of OVA. Statistical analysis of the data using a Student's t-test revealed that the induction of T cell non-responsiveness to Der p 1 is significant at P Ͻ 0.05 between PBS-and peptide-treated animals, while the lowered OVA responses were not statistically significant between PBS-or p111-139-treated animals (P Ͼ 0.1).
regulated following tolerance induction with a peptide conized under T h 2-type conditions. Therefore, the mucosally delivered peptide tolerogen appears to affect the function of taining either the dominant or a minor T cell epitope. Although the level of T cell inhibition achieved with the minor T cell CD4 ϩ T h cells while B cell function in the short term does not appear to be modulated. These findings are consistent with epitope was not as profound as that obtained with the immunodominant epitope, our results are in agreement with studies which have examined immunological functions of patients who have undergone conventional allergen immunoother reports (9,13) that demonstrate a hierarchy of potency of peptides as tolerogens which reflects their immunogenicity therapy (31), where T cell functions were demonstrated to have been modulated without affecting the levels of specific in vivo. The finding that there is a loss of cytokine production by antigen-specific T cells following tolerance induction is serum IgE in the short term. A feature of mucosal tolerance induced by nasally adminisconsistent with a previous study on peptide-induced peripheral tolerance (28). However, there may be distinct mechantered peptide is that a single peptide can inhibit responses to all epitopes on an antigen (13-17). In the model system isms which operate in the induction of mucosal tolerance through the respiratory tract and this may be dependent studied here, the induction of tolerance to the immunodominant peptide of Der p 1 can down-regulate T cell responses upon the dose, the frequency and the nature of the antigen administered, as has been shown for oral tolerance (29) .
to all four epitopes on the antigen when mice are immunized with the whole protein in adjuvant (15). However, it was Although the nasal administration of soluble peptide appears to induce a strong primary immune response (6), possible to uncouple tolerance to the minor epitopes by immunizing tolerant mice with a peptide containing only the the functional outcome of this response is qualitatively different had the same peptide been administered in conjunction subdominant determinant, which is consistent with previous studies on peripheral T cell tolerance (8). However, it was with adjuvant. We have previously suggested that mucosal tolerance to high-dose peptide induces a population of regupossible to rescue a T cell response to a minor epitope of Der p 1 in mice that had been rendered tolerant to the latory T cells which display an anergic phenotype in vitro (6). The cells remain in the peripheral circulation but can no dominant epitope and who had been previously immunized with the whole protein (Fig. 5 ). If such mice were immunized longer act as classical T h cells (15,16) but instead adopt an immunoregulatory role and function to modulate rather than with the subdominant peptide in adjuvant, 3 weeks after the initial protein immunization, then the previously tolerant mice promote antigen-specific immune responses. Furthermore, these regulatory T cells appear to be maintained in the displayed equivalent responses to the subdominant epitope as controls. peripheral circulation for long periods, as evidenced by their capacity to down-regulate T cell-dependent immune Taken together, these observations suggest that the T cells specific for the minor epitopes are not deleted or anergized responses, such as cytokine secretion and DTH responses to Der p 1. Moreover, the regulatory T cells appear to be after nasal administration of the immunodominant peptide, but should be competent to respond to their epitopes following functional even 6 months after the original peptide treatment. This finding is in agreement with the stability of oral tolerance immunization with the protein. Yet this is not the case. Thus the intramolecular epitope suppression observed in our model in mice where a single feed of protein to a naive animal can lead to life long antigen-specific T cell non-responsiveness is probably due to local suppression mediated by regulatory CD4 ϩ T cells through the recognition of linked epitopes on (30) .
Although antigen-specific T cell responses were modulated the same antigen. However, rather than killing the T cells specific for minor epitopes, we suggest that the regulatory following tolerance induction, the levels of specific IgE antibody were not affected. The limitation to this study was that T cells may merely block their growth. Once the immune response to the protein has waned, the regulatory T cells most immunizations were made in CFA which should bias for a T h 1 dominant immune response. Nevertheless, we have would return to a resting state since their epitopes would not be presented on APC. Thus when tolerant mice are also observed similar findings when mice were also immun- linked suppression is not new and has been observed in a murine model of mAb-induced transplantation tolerance (18, 19) . Regulatory CD4 ϩ T cells induced by this tolerance References protocol can mediate local suppression of allo-reactive T cells by linked recognition of antigen possibly on the same APC
